MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition
Authors
Keywords
-
Journal
JOURNAL OF EXPERIMENTAL MEDICINE
Volume 209, Issue 4, Pages 679-696
Publisher
Rockefeller University Press
Online
2012-03-20
DOI
10.1084/jem.20111512
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pathologic Complete Response Predicts Recurrence-Free Survival More Effectively by Cancer Subset: Results From the I-SPY 1 TRIAL—CALGB 150007/150012, ACRIN 6657
- (2012) Laura J. Esserman et al. JOURNAL OF CLINICAL ONCOLOGY
- Exploiting synthetic lethal interactions for targeted cancer therapy
- (2011) H. Christian Reinhardt et al. CELL CYCLE
- Altered Subcellular Localization of c-Myc Protein Identifies Aggressive B-cell Lymphomas Harboring a c-MYC Translocation
- (2010) Marianna B. Ruzinova et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Breast Cancer Subtypes and the Risk of Local and Regional Relapse
- (2010) K. David Voduc et al. JOURNAL OF CLINICAL ONCOLOGY
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
- (2010) Andrew Tutt et al. LANCET
- Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
- (2010) David Parry et al. MOLECULAR CANCER THERAPEUTICS
- Adaptive trials receive boost
- (2010) Dan Jones NATURE REVIEWS DRUG DISCOVERY
- Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase
- (2010) D. Yang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A pathway-based classification of human breast cancer
- (2010) M. L. Gatza et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Androgen Receptor Levels and Association with PIK3CA Mutations and Prognosis in Breast Cancer
- (2009) A. M. Gonzalez-Angulo et al. CLINICAL CANCER RESEARCH
- I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy
- (2009) AD Barker et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
- (2009) Maggie C. U. Cheang et al. JNCI-Journal of the National Cancer Institute
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mimicking the BH3 domain to kill cancer cells
- (2009) T Ni Chonghaile et al. ONCOGENE
- Meta-Analysis and Gene Set Enrichment Relative to ER Status Reveal Elevated Activity of MYC and E2F in the “Basal” Breast Cancer Subgroup
- (2009) M. Chehani Alles et al. PLoS One
- A Core MYC Gene Expression Signature Is Prominent in Basal-Like Breast Cancer but Only Partially Overlaps the Core Serum Response
- (2009) Sanjay Chandriani et al. PLoS One
- Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells
- (2009) J. J. Molenaar et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Epithelial-Mesenchymal Transition in Breast Cancer Relates to the Basal-like Phenotype
- (2008) D. Sarrio et al. CANCER RESEARCH
- An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer
- (2008) K. Stemke-Hale et al. CANCER RESEARCH
- Module Map of Stem Cell Genes Guides Creation of Epithelial Cancer Stem Cells
- (2008) David J. Wong et al. Cell Stem Cell
- Triple-Negative Breast Cancer: Risk Factors to Potential Targets
- (2008) B. P. Schneider et al. CLINICAL CANCER RESEARCH
- What is triple-negative breast cancer?
- (2008) William J. Irvin et al. EUROPEAN JOURNAL OF CANCER
- Myc's broad reach
- (2008) M. Eilers et al. GENES & DEVELOPMENT
- How basal are triple-negative breast cancers?
- (2008) François Bertucci et al. INTERNATIONAL JOURNAL OF CANCER
- Cdk5-mediated Phosphorylation of c-Myc on Ser-62 Is Essential in Transcriptional Activation of Cyclin B1 by Cyclin G1
- (2008) Haeng Ran Seo et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
- (2008) Cornelia Liedtke et al. JOURNAL OF CLINICAL ONCOLOGY
- Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis
- (2008) Bora Gurel et al. MODERN PATHOLOGY
- Multisite Phosphorylation Regulates Bim Stability and Apoptotic Activity
- (2008) Anette Hübner et al. MOLECULAR CELL
- Modelling Myc inhibition as a cancer therapy
- (2008) Laura Soucek et al. NATURE
- An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumors
- (2008) Ittai Ben-Porath et al. NATURE GENETICS
- Prognostic Breast Cancer Signature Identified from 3D Culture Model Accurately Predicts Clinical Outcome across Independent Datasets
- (2008) Katherine J. Martin et al. PLoS One
- Covalent capture of kinase-specific phosphopeptides reveals Cdk1-cyclin B substrates
- (2008) J. D. Blethrow et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CDK inhibitors in cancer therapy: what is next?
- (2007) Marcos Malumbres et al. TRENDS IN PHARMACOLOGICAL SCIENCES
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More